心血管病生物靶向治疗的新时代到来  

The advent of a new era of biological target therapy for cardiovascular diseases

作　　者：廖玉华[1] 邱志华[1] 陈霄[1] 

机构地区：[1]华中科技大学同济医学院心血管病研究所、附属协和医院心内科、教育部生物靶向治疗研究重点实验室,武汉430022

出　　处：《临床心血管病杂志》2016年第1期1-3,共3页Journal of Clinical Cardiology

摘　　要：慢性心血管病严重危害人类健康,治疗现状不容乐观。生物靶向治疗技术如抗体、疫苗、基因、干细胞等靶向性强、作用时间长且治疗效应平稳,对于改变慢性心血管病的治疗现状,降低其患病率和病死率具有重要意义。随着PCSK9单抗的成功上市,心血管病生物靶向治疗的新时代已然到来。Chronic cardiovascular diseases constitute a serious hazard to human health,and the present status of treatment is not optimistic.Biological target therapeutic techniques（antibodies,vaccines,gene,stem cell）,possess several advantages as compared with other drugs,such as long-acting time,strong targeting ability and smooth effect.Biological target therapeutic techniques can significantly improve current treatment status,and reduce the morbidity and mortality of chronic cardiovascular diseases.The PCSK9 monoclonal antibodies had been approved into the market,indicating the advent of a new era of biological target therapy for cardiovascular diseases.

关 键 词：心血管病 生物靶向治疗 单克隆抗体 疫苗 基因治疗 干细胞治疗 

分 类 号：R541[医药卫生—心血管疾病]